There is a lot of excitement in our market over the new rules we introduced earlier this month to welcome new economy and pre-revenue biotech companies. We’ve already had several companies express interest in listing under the new rules, and we’ve heard a lot of positive things from investors who are excited about being able to invest in some of today’s most dynamic companies right here in Hong Kong. While it’s exciting to have access to the new economy, some of these companies come from sectors that are not as familiar to Hong Kong investors. We have a lot of retail investors in our market and a strong regulatory regime that strives to protect investors as much as possible — but there are still inherent risks when investing in any company. Biotech, in particular, is one field where companies could become a wild success or flame out into nothing, quickly.
To read more, please go to http://www.hkexgroup.com/media-centre/charles-li-direct/2018/bracing-for-the-ups-and-downs-of-biotech?sc_lang=zh-HK